Uma Goyal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Uma Goyal has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Baldassarre Stea
University of Arizona, Department of Radiation Oncology, Tucson, Arizona
4 shared publicationsBrady Laughlin
Mayo Clin, Dept Radiat Oncol, Phoenix, AZ USA
2 shared publicationsDenise Roe
Department of Epidemiology and Biostatistics, University of Arizona Cancer Center, Tucson, AZ
2 shared publicationsHaiyan Cui
University of Arizona Mel and Enid Zuckerman College of Public Health, Tucson, USA
2 shared publicationsJohn Gordon
Intermt Healthcare, Salt Lake City, UT USA
2 shared publicationsJustin Suszko
RadiantCare, Lacey, WA USA
2 shared publications
Latest Publications
- 30 January 2023
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 54 (4) , 1-3
Definitive Chemoradiation for Colon Cancer: a Case Report
- 30 January 2023
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 54 (4) , 1-3
Definitive Chemoradiation for Colon Cancer: a Case Report
- Open Access
- 26 July 2022
- Published by Springer Nature in Cureus
- Vol. 14 (7) , e27300
Gastrointestinal Cancer Found in the Cervix With Unknown Primary Site and Treated With Definitive Chemoradiation
Locally advanced gastrointestinal cancers and cervical cancers are usually treated with a multimodality approach. Our case report shows a patient who was found to have gastrointestinal cancer in the cervix, and no primary gastrointestinal cancer was found on workup. She underwent chemoradiation to the pelvis with concurrent capecitabine and then underwent cervical brachytherapy with tandem and ovoid. She initially had done well but then noticed increased symptoms at follow-ups. Unfortunately, she was found to have residual disease about 16 months after the completion of treatment. There have been no reports of treatment of gastrointestinal cancer in the cervix with an unknown primary site in the literature to our knowledge.
- 26 July 2022
- Published by Springer Nature in Cureus
- Vol. 14 (7) , e27300
Open AccessGastrointestinal Cancer Found in the Cervix With Unknown Primary Site and Treated With Definitive Chemoradiation
Locally advanced gastrointestinal cancers and cervical cancers are usually treated with a multimodality approach. Our case report shows a patient who was found to have gastrointestinal cancer in the cervix, and no primary gastrointestinal cancer was found on workup. She underwent chemoradiation to the pelvis with concurrent capecitabine and then underwent cervical brachytherapy with tandem and ovoid. She initially had done well but then noticed increased symptoms at follow-ups. Unfortunately, she was found to have residual disease about 16 months after the completion of treatment. There have been no reports of treatment of gastrointestinal cancer in the cervix with an unknown primary site in the literature to our knowledge.
- 1 August 2021
- Published by Elsevier in Clinical Breast Cancer
- Vol. 21 (4) , e295-e301
Prone Positioning With Deep Inspiration Breath Hold for Left Breast Radiotherapy
- 1 August 2021
- Published by Elsevier in Clinical Breast Cancer
- Vol. 21 (4) , e295-e301
Prone Positioning With Deep Inspiration Breath Hold for Left Breast Radiotherapy
- Open Access
- 1 January 2021
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 13 (5) , 497-503
Electronic brachytherapy for treatment of non-melanoma skin cancers: clinical results and toxicities
Introduction Although surgical approaches are standard for most non-melanomatous skin cancers, some patients are not candidates due to medical co-morbidities or functional or cosmetic or lesion location. High-dose-rate electronic brachytherapy (HDR-EBT) may be an alternative treatment modality....
- 1 January 2021
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 13 (5) , 497-503
Open AccessElectronic brachytherapy for treatment of non-melanoma skin cancers: clinical results and toxicities
Introduction Although surgical approaches are standard for most non-melanomatous skin cancers, some patients are not candidates due to medical co-morbidities or functional or cosmetic or lesion location. High-dose-rate electronic brachytherapy (HDR-EBT) may be an alternative treatment modality....
- Open Access
- 1 January 2021
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 13 (3) , 280-285
Reproducibility of vaginal immobilization balloons in situ overnight for cervical cancer brachytherapy
Introduction The use of vaginal immobilization balloons placed into the vagina for immobilization of tandem and ovoid (T + O) applicator during high-dose-rate (HDR) brachytherapy delivery has been used at our institution, and seems to have improved our patient comfort, decreased procedure time,...
- 1 January 2021
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 13 (3) , 280-285
Open AccessReproducibility of vaginal immobilization balloons in situ overnight for cervical cancer brachytherapy
Introduction The use of vaginal immobilization balloons placed into the vagina for immobilization of tandem and ovoid (T + O) applicator during high-dose-rate (HDR) brachytherapy delivery has been used at our institution, and seems to have improved our patient comfort, decreased procedure time,...
- Open Access
- 19 October 2020
- Published by Springer Nature in Cureus
- Vol. 12 (10)
Definitive Chemoradiation With Dose Escalation for Locally Advanced Gastric Cancer: Case Studies
Gastric cancer is a prevalent cancer with a predilection for Asian ethnicity and male patients. In early and locally advanced gastric cancer, without significant comorbidities, surgery is a part of the treatment management of this cancer. However, with concurrent comorbidities, surgery may not be recommended and alternative treatment options such as palliative chemotherapy and/or radiation and definitive chemoradiation can be considered to reduce morbidity. We present three cases of gastric cancer where definitive chemoradiation with dose escalation was utilized due to underlying comorbidities and poor performance status. The treatment was generally well tolerated by patients and resulted in substantial reduction in gastric mass size in two patients with median overall survival of 10 months.
- 19 October 2020
- Published by Springer Nature in Cureus
- Vol. 12 (10)
Open AccessDefinitive Chemoradiation With Dose Escalation for Locally Advanced Gastric Cancer: Case Studies
Gastric cancer is a prevalent cancer with a predilection for Asian ethnicity and male patients. In early and locally advanced gastric cancer, without significant comorbidities, surgery is a part of the treatment management of this cancer. However, with concurrent comorbidities, surgery may not be recommended and alternative treatment options such as palliative chemotherapy and/or radiation and definitive chemoradiation can be considered to reduce morbidity. We present three cases of gastric cancer where definitive chemoradiation with dose escalation was utilized due to underlying comorbidities and poor performance status. The treatment was generally well tolerated by patients and resulted in substantial reduction in gastric mass size in two patients with median overall survival of 10 months.
- Open Access
- 23 July 2019
- Published by Springer Nature in Cureus
- Vol. 11 (7) , e5214
Pathologic Complete Response After Neoadjuvant Chemoradiation in a Patient with Gastric Neuroendocrine Cancer
Neuroendocrine tumors are about 0.5% of all malignancies. Specifically, for gastrointestinal (GI) malignancies, neuroendocrine tumor incidence is approximately 1%-2% per year. Gastric neuroendocrine neoplasms are rare and consist of various tumor types with differing histomorphology, pathogenesis, and biological behavior. Following surgery, post-operative chemotherapy is generally considered the standard of care. Our case report demonstrates the potential benefit of neoadjuvant concurrent chemoradiotherapy prior to surgery for a malignant gastric neuroendocrine tumor. While radiotherapy has been demonstrated to possibly provide a survival benefit in the treatment of GI neuroendocrine tumors, its use in treatment, particularly neoadjuvantly, needs to be further assessed.
- 23 July 2019
- Published by Springer Nature in Cureus
- Vol. 11 (7) , e5214
Open AccessPathologic Complete Response After Neoadjuvant Chemoradiation in a Patient with Gastric Neuroendocrine Cancer
Neuroendocrine tumors are about 0.5% of all malignancies. Specifically, for gastrointestinal (GI) malignancies, neuroendocrine tumor incidence is approximately 1%-2% per year. Gastric neuroendocrine neoplasms are rare and consist of various tumor types with differing histomorphology, pathogenesis, and biological behavior. Following surgery, post-operative chemotherapy is generally considered the standard of care. Our case report demonstrates the potential benefit of neoadjuvant concurrent chemoradiotherapy prior to surgery for a malignant gastric neuroendocrine tumor. While radiotherapy has been demonstrated to possibly provide a survival benefit in the treatment of GI neuroendocrine tumors, its use in treatment, particularly neoadjuvantly, needs to be further assessed.
- 1 September 2017
- Published by Elsevier in Practical Radiation Oncology
- Vol. 7 (5) , 302-305
Irinotecan-induced radiation-recall myositis in a patient with metastatic breast cancer: A case report
- 1 September 2017
- Published by Elsevier in Practical Radiation Oncology
- Vol. 7 (5) , 302-305
Irinotecan-induced radiation-recall myositis in a patient with metastatic breast cancer: A case report
- 1 May 2017
- Published by Elsevier in Practical Radiation Oncology
- Vol. 7 (3) , e233-e241
Radiotherapeutic management of vestibular schwannomas using size- and location-adapted fractionation regimens to maximize the therapeutic ratio
- 1 May 2017
- Published by Elsevier in Practical Radiation Oncology
- Vol. 7 (3) , e233-e241
Radiotherapeutic management of vestibular schwannomas using size- and location-adapted fractionation regimens to maximize the therapeutic ratio
- Open Access
- 1 January 2017
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 1 (1) , 14-19
Does ultrasound measurement improve the accuracy of electronic brachytherapy in the treatment of superficial non-melanomatous skin cancer?
Purpose: Electronic brachytherapy (eBT) is a form of contact radiation therapy used for thin superficial non-melanomatous skin cancers (NMSCs). An accurate measurement of diameter and depth is important for eBT treatment planning. Therefore, we compared clinical measurements by an experienced...
- 1 January 2017
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 1 (1) , 14-19
Open AccessDoes ultrasound measurement improve the accuracy of electronic brachytherapy in the treatment of superficial non-melanomatous skin cancer?
Purpose: Electronic brachytherapy (eBT) is a form of contact radiation therapy used for thin superficial non-melanomatous skin cancers (NMSCs). An accurate measurement of diameter and depth is important for eBT treatment planning. Therefore, we compared clinical measurements by an experienced...